Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study.

Peter HunyadyLea StrellerDarius F RütherSara Reinartz GrobaDominik BettingerDaniel FittingKarim HameschJens U MarquardtVictoria T MückeFabian FinkelmeierAsieb SekandarzadTobias WengenmayerAyoub BounidaneFelicitas WeissKai Henrik PeifferBernhard SchlevogtStefan ZeuzemOliver WaidmannMarcus HollenbachMartha M KirsteinJohannes KluweFabian KüttingMarcus Maximilian Mücke

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

COVID-SSC and CIP-SSC share the same clinical phenotype, course of the disease and risk factors for its development. UDCA may be a promising therapeutic option in SSC, though future prospective trials need to confirm our findings.

Keyphrases

coronavirus disease
sars cov
cross sectional
current status
clinical trial